Cargando…
The national economic burden of rare disease in the United States in 2019
BACKGROUND: To provide a comprehensive assessment of the total economic burden of rare diseases (RD) in the United States (U.S.) in 2019. We followed a prevalence-based approach that combined the prevalence of 379 RDs with the per-person direct medical and indirect costs, to derive the national econ...
Autores principales: | Yang, Grace, Cintina, Inna, Pariser, Anne, Oehrlein, Elisabeth, Sullivan, Jamie, Kennedy, Annie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004040/ https://www.ncbi.nlm.nih.gov/pubmed/35414039 http://dx.doi.org/10.1186/s13023-022-02299-5 |
Ejemplares similares
-
The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs
por: Bebo, Bruce, et al.
Publicado: (2022) -
Current and projected future economic burden of Parkinson’s disease in the U.S.
por: Yang, Wenya, et al.
Publicado: (2020) -
The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)
por: Greenberg, Paul, et al.
Publicado: (2023) -
The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes
por: Dall, Timothy M., et al.
Publicado: (2019) -
Economic Burden of Sanfilippo Syndrome in the United States
por: Ashby, Frederick, et al.
Publicado: (2023)